Abstract:Many patients with type 2 diabetes will ultimately require the inclusion of basal insulin in their treatment regimen. Since most people with type 2 diabetes are managed in the community, it is important that primary care providers understand and correctly manage the initiation and titration of basal insulins, and help patients to self-manage insulin injections. Newer, long-acting basal insulins provide greater stability and flexibility than older preparations and improved delivery systems. Basal insulin is usually initiated at a conservative dose of 10 units/day or 0.1-0.2 units/kg/day, then titrated thereafter over several weeks or months, based on patients' self-measured fasting plasma glucose, to achieve an individualized target (usually 80-130 mg/dL). Through a shared decision-making process, confirmation of appropriate goals and titration methods should be established, including provisions for events that might alter scheduled titration (e.g. travel, dietary change, illness, hospitalization, etc.). Although switching between basal insulins is usually easily accomplished, pharmacokinetic and pharmacodynamic differences between formulations require clinicians to provide explicit guidance to patients. Basal insulin is effective long-term, but overbasalization (continuing to escalate dose without a meaningful reduction in fasting plasma glucose) should be avoided.Key messagesPrimary care providers often initiate basal insulin for people with type 2 diabetes.Basal insulin is recommended to be initiated at 10 units/day or 0.1-0.2 units/kg/day, and doses must be titrated to agreed fasting plasma glucose goals, usually 80-130 mg/dL. A simple rule is to gradually increase the initial dose by 1 unit per day (NPH, insulin detemir, and glargine 100 units/mL) or 2-4 units once or twice per week (NPH, insulin detemir, glargine 100 and 300 units/mL, and degludec) until FPG levels remain consistently within the target range. If warranted, switching between basal insulins can be done using simple regimens.The dose of basal insulin should be increased as required up to approximately 0.5-1.0 units/kg/day in some cases. Overbasalization (continuing to escalate dose without a meaningful reduction in fasting plasma glucose) is not recommended; rather re-evaluation of individual therapy, including consideration of more concentrated basal insulin preparations and/or short-acting prandial insulin as well as other glucose-lowering therapies, is suggested.

Proportion and characteristics of patients with Type 2 diabetes mellitus initiating basal insulin therapy using a basal-bolus regimen

Observational Registry of Basal Insulin Treatment (ORBIT) in Patients with Type 2 Diabetes Uncontrolled with Oral Antihyperglycaemic Drugs: Real-life Use of Basal Insulin in China.

Patient characteristics and 6-month dose of basal insulin associated with HbA1c achievement <7.0% in Chinese people with type 2 diabetes: results from the Observational Registry of Basal Insulin Treatment (ORBIT).

Changes of health-related quality of life after initiating basal insulin treatment among people with type 2 diabetes

Status of Basal-Supported Oral Therapy in Chinese Type 2 Diabetic Patients with Inadequate Glycemic Control on Oral Anti-Diabetic Drugs

Observational Registry of Basal Insulin Treatment (ORBIT) in Patients with Type 2 Diabetes Uncontrolled by Oral Hypoglycemic Agents in China--Study Design and Baseline Characteristics.

Predictors of Glycemic Control in Patients with Type 2 Diabetes: A Subgroup Analysis of the Observational Registry of Basal Insulin Treatment Study in China

The Safety and Efficacy of Initiating Insulin Therapy in Chinese Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Previous Oral Antidiabetic Drugs

Observational Registry of Basal Insulin Treatment in Patients with Type 2 Diabetes in China: Safety and Hypoglycemia Predictors

Effectiveness and Safety of Basal Insulin Therapy in Type 2 Diabetes Mellitus Patients with or Without Metformin Observed in a National Cohort in China

A Pragmatic Study of Mid‐mixture Insulin and Basal Insulin Treatment in Patients with Type 2 Diabetes Uncontrolled with Oral Antihyperglycaemic Medications: A Lesson from Real‐world Experience

Where to Initiate Basal Insulin Therapy: Inpatient or Outpatient Department? Real-World Observation in China.

Cost Change After Initiating Basal Insulin for 6 Months in Patients with Type 2 Diabetes: A Registry Study in China

Efficacy and Safety of Additional Basal Insulin or Oral Antidiabetic Drug in Type 2 Diabetes Poorly Controlled with One Oral Antidiabetic Drug

Effects of basal and premixed insulin on glycemic control in type 2 diabetes patients based on multicenter prospective real-world data

Survey of Glycemic Control in Type 2 Diabetic Patients Treated with Human Insulin in China

Safety and Efficacy of High Versus Standard Starting Doses of Insulin Glargine in Overweight and Obese Chinese Individuals with Type 2 Diabetes Mellitus Inadequately Controlled on Oral Antidiabetic Medications (beyond VII): Study Protocol for a Randomized Controlled Trial

Practical guidance on the initiation, titration, and switching of basal insulins: a narrative review for primary care

The Impact of Initiating Biphasic Human Insulin 30 Therapy in Type 2 Diabetes Patients after Failure of Oral Antidiabetes Drugs

Efficacy and safety of basal-bolus insulin at 1:1.5 ratio compared to 1:1 ratio using a weight-based initiation and titration (WIT2) algorithm in hospitalized patients with type 2 Diabetes: a multicenter, randomized, clinical study

Basal Insulin Initiation in Adults With Type 2 Diabetes Mellitus: A Retrospective Cohort Study Using Administrative Health Data in Alberta, Canada